There is growing evidence suggesting a potential clinical benefit of PARP inhibitors in patients with one of the classical HRD‐associated cancer types, in whom a BRIP1 mutation has been identified [26]. This evidence concerns the gene BRIP1 and hypoparathyroidism-retardation-dysmorphism syndrome.